Search

GlaxoSmithKline PLC

Aperta

SettoreSettore sanitario

2,247 -0.93

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

2246

Massimo

2281

Metriche Chiave

By Trading Economics

Entrata

-1.5B

636M

Vendite

71M

8.6B

P/E

Media del settore

15.712

110.024

EPS

0.255

Rendimento da dividendi

3.05

Margine di Profitto

7.38

Dipendenti

68,629

EBITDA

-1.2B

2.2B

Raccomandazioni

By TipRanks

Raccomandazioni

Neutrale

Previsioni per 12 mesi

-10.94% downside

Dividendi

By Dow Jones

Rendimento da dividendi

Media del settore

3.05%

2.26%

Utili prossimi

29 apr 2026

Prossima data del Dividendo

9 apr 2026

Prossima data del' Ex Dividendo

19 feb 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

10B

88B

Apertura precedente

2247.93

Chiusura precedente

2247

Notizie sul Sentiment di mercato

By Acuity

34%

66%

103 / 351 Classifica in Healthcare

GlaxoSmithKline PLC Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

4 feb 2026, 07:46 UTC

Utili

GSK's Specialty Medicines Drive Solid Results

20 gen 2026, 11:34 UTC

I principali Market Mover
Acquisizioni, Fusioni, Takeovers

RAPT Therapeutics Shares Jump Following Acquisition by GSK

20 gen 2026, 10:40 UTC

Acquisizioni, Fusioni, Takeovers

GSK to Acquire RAPT for $2.2 Billion to Bolster Food Allergy Treatments -- Update

20 gen 2026, 07:47 UTC

Acquisizioni, Fusioni, Takeovers

GSK to Acquire RAPT for $2.2 Billion to Bolster Food Allergy Treatments

4 feb 2026, 13:12 UTC

Discorsi di Mercato
Utili

GSK Could Still Face U.S. Drug Pricing Headwind -- Market Talk

4 feb 2026, 08:25 UTC

Discorsi di Mercato
Utili

GSK's Guidance Implies FX Headwind -- Market Talk

4 feb 2026, 07:06 UTC

Utili

GSK 4Q Core Operating Margin 19.0%

4 feb 2026, 07:05 UTC

Utili

GSK: 2031 Sales Outlook More Than GBP40B

4 feb 2026, 07:03 UTC

Utili

GSK Expects 2026 Core Operating Profit Growth of Between 7% to 9%

4 feb 2026, 07:03 UTC

Utili

GSK Expects 2026 Sales Growth of Between 3% to 5%

4 feb 2026, 07:01 UTC

Utili

Analysts Had GSK 4Q Core Operating Profit at GBP1.53B

4 feb 2026, 07:01 UTC

Utili

GSK 4Q Core Operating Profit GBP 1.63B

4 feb 2026, 07:01 UTC

Utili

Analysts Had GSK 4Q Sales at GBP8.495B

4 feb 2026, 07:00 UTC

Utili

GSK Issues 2026 View

4 feb 2026, 07:00 UTC

Utili

GSK PLC 4Q EPS 15.6p

4 feb 2026, 07:00 UTC

Utili

GSK PLC 4Q Adj EPS 25.5p

4 feb 2026, 07:00 UTC

Utili

GSK PLC 4Q Turnover GBP8.62B

4 feb 2026, 07:00 UTC

Utili

GSK PLC 4Q Pre-items, Pretax Pft GBP1.48B

4 feb 2026, 07:00 UTC

Utili

GSK PLC 4Q Oper Pft GBP1.1B

4 feb 2026, 07:00 UTC

Utili

GSK PLC 4Q Pretax Pft GBP950M

20 gen 2026, 21:45 UTC

Acquisizioni, Fusioni, Takeovers

This Biotech Stock Surges 64%. The Big Pharma M&A Battle Is Heating Up. -- Barrons.com

20 gen 2026, 14:53 UTC

Acquisizioni, Fusioni, Takeovers

This Biotech Stock Surges 64%. The Big Pharma M&A Battle Is Heating Up. -- Barrons.com

20 gen 2026, 13:50 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

GSK's RAPT Deal Helps Address Looming Drug Patent Cliff -- Market Talk

20 gen 2026, 13:28 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

GSK's Deal to Buy RAPT Is the Right Risk -- Market Talk

20 gen 2026, 12:10 UTC

Acquisizioni, Fusioni, Takeovers

This Biotech Stock Surges 64%. The Big Pharma M&A Battle Is Heating Up. -- Barrons.com

20 gen 2026, 07:15 UTC

Acquisizioni, Fusioni, Takeovers

GSK Expects to Complete RAPT Buy in 1Q

20 gen 2026, 07:15 UTC

Acquisizioni, Fusioni, Takeovers

GSK: RAPT Buy Subject to Customary Closing Conditions

20 gen 2026, 07:14 UTC

Acquisizioni, Fusioni, Takeovers

GSK to Launch Tender Offer to Buy RAPT Common Stock Within 10 Business Days

20 gen 2026, 07:14 UTC

Acquisizioni, Fusioni, Takeovers

GSK: Ozureprubart Rights Exclude Mainland China, Macau, Taiwan, Hong Kong

20 gen 2026, 07:13 UTC

Acquisizioni, Fusioni, Takeovers

GSK Gets Global Rights to the Ozureprubart Program Under RAPT Deal

GlaxoSmithKline PLC Previsione

Obiettivo di Prezzo

By TipRanks

-10.94% in calo

Previsioni per 12 mesi

Media 1,928.21 GBX  -10.94%

Alto 2,450 GBX

Basso 1,500 GBX

Basato su 15 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per GlaxoSmithKline PLC - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Neutrale

15 ratings

3

Acquista

8

Mantieni

4

Vendi

Sentiment

By Acuity

103 / 351 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo GlaxoSmithKline PLC

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development; two strategic collaborations with Relation to advance therapeutics for fibrotic diseases and osteoarthritis; and multi-target strategic alliance with GSK to develop breakthrough treatments for people afflicted with Parkinson's disease; as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.dom.
help-icon Live chat